Table 2 Demographic and clinical characteristics of COVID-19 positive Individuals
Characteristic | A8G6 (N = 12) | Control (N = 151) | P value |
|---|---|---|---|
Age | 0.103 | ||
Median age (IQR, year) | 36.0 (31.2–45.5) | 42.0 (32.0–51.0) | |
Mean ± sd | 36.3 ± 10.4 | 41.8 ± 12.0 | |
Sex | 0.375 | ||
Male | 8 (66.7%) | 77 (51.0%) | |
Female | 4 (33.3%) | 74 (49.0%) | |
Weight (mean ± sd) | 61.5 (58.8–66.2) | 63.0 (55.0–70.0) | 0.934 |
BMI (mean ± sd) | 21.4 (20.9–23.2) | 23.7 (21.4–26.0) | 0.057 |
Clinical phenotype | 0.694 | ||
Symptomatic | 11 (91.7%) | 127 (84.1%) | |
Asymptomatic | 1 (8.3%) | 24 (15.9%) | |
Duration from exposure to COVID-19 confirmed (day) | 0.019 | ||
median days, IQR | 3.5 (2.8–4.0) | 3.0 (2.0–3.0) | |
Mean ± sd | 3.4 ± 1.1 | 2.6 ± 1.2 | |
Duration of SARS-CoV-2 positive (day) | 0.724 | ||
median days, IQR | 6.5 (5.0–7.2) | 7.0 (4.0–7.0) | |
Mean ± sd | 6.7 ± 1.9 | 6.3 ± 2.5 | |
Viral load (Conversion according to Ct value) of ORF1ab gene) | 1.000 | ||
High level, >105 copies/ml | 5 (41.7%) | 69 (45.7%) | |
Low level, <105 copies/ml | 7 (58.3%) | 82 (54.3%) | |
Viral load (Conversion according to Ct value) of N gene) | 0.117 | ||
High level, >105 copies/ml | 5 (41.7%) | 100 (66.2%) | |
Low level, <105 copies/ml | 7 (58.3%) | 51 (33.8%) | |
Symptomatic treatment | 0.039 | ||
Western medicine | 11 (91.7%) | 89 (58.9%) | |
Traditional chinese medicine | 0 (0.0%) | 8 (5.3%) | |
Combination of western and traditional chinese medicine | 1 (8.3%) | 6 (4.0%) | |
Untreated | 0 (0.0%) | 48 (31.8%) | |
Duration of Covid-19 symptoms (d) | 0.401 | ||
median days, IQR | 5.0 (1.5–5.0) | 3.0 (2.0–4.5) | |
Mean ± sd | 4.3 ± 2.9 | 4.2 ± 5.0 | |
Comorbidities | 0.435 | ||
Metabolic disease | 1 (8.3%) | 17 (11.3%) | |
Respiratory disease | 1 (8.3%) | 2 (1.3%) | |
Cardiovascular diseases | 0 (0.0%) | 1 (0.7%) | |
Other | 1 (8.3%) | 5 (3.3%) | |
All | 3 (25.0%) | 25 (16.6%) | |
Vaccine type | 0.203 | ||
Inactivated vaccine | 10 (83.3%) | 143 (94.7%) | |
Recombinant vaccine | 2 (16.7%) | 5 (3.3%) | |
Unvaccinated | 0 (0.0%) | 3 (2.0%) | |
Dose | 1.000 | ||
0-dose | 0 (0.0%) | 3 (2.0%) | |
1-dose | 0 (0.0%) | 1 (0.7%) | |
2-dose | 2 (16.7%) | 24 (15.9%) | |
3-dose | 10 (83.3%) | 123 (81.5%) | |
Duration from last vaccination to exposure (day) | 359.5 (272.2–456.2) | 384.0 (299.5–463.0) | 0.622 |
Signs and symptomsa | |||
Fever | 10 (83.3%) | 83 (55.0%) | 0.071 |
Fatigue | 4 (33.3%) | 22 (14.6%) | 0.102 |
Dry cough | 6 (50.0%) | 54 (35.8%) | 0.361 |
Headache | 3 (25.0%) | 39 (25.8%) | 1.000 |
Dizziness | 0 (0.0%) | 5 (3.3%) | 1.000 |
Ageusia | 2 (16.7%) | 8 (5.3%) | 0.161 |
Pharyngalgia | 1 (8.3%) | 12 (7.9%) | 1.000 |
Myalgia | 2 (16.7%) | 37 (24.5%) | 0.733 |
Chill | 1 (8.3%) | 3 (2.0%) | 0.266 |
